The National Health Surveillance Agency (Anvisa) approved this Thursday (20) the application of the immunizing CoronaVac in children and adolescents aged between 6 and 17 years – except in cases of immunosuppressed minors (with low immunity). The decision was taken during an extraordinary meeting of the collegiate board.
Children and adolescents with comorbidities may also receive the vaccine, which will be administered in two doses, with an interval of 28 days. The vaccine is the same currently used in the immunization of adults, without any type of adaptation for a pediatric version.
The decision was unanimous. In all, five directors voted in favor of the release: Meiruze Sousa Freitas, Alex Machado Campos, Rômison Rodrigues Mota, Cristiane Rose Jourdan and Anvisa’s CEO, Antônio Barra Torres.
Through social networks, the Minister of Health, Marcelo Queiroga, commented on the approval of the emergency use of CoronaVac for the age group from 6 to 17 years. “All vaccines authorized by Anvisa are considered for the PNO [Plano Nacional de Operacionalização da Vacinação contra Covid-19]. We await the entire decision and its publication in the DOU,” he said on his Twitter account.
Butantan
By means of a note, the Butantan Institute, manufacturer of CoronaVac in partnership with the Chinese biopharmaceutical company Sinovac, informed that the authorization took place after evaluation of an application sent to Anvisa on December 15, based on safety studies and immune response from countries such as Chile, China, South Africa, Thailand and also Brazil.
“CoronaVac is scientifically proven to be the safest vaccine with the fewest adverse effects, in addition to being the most used vaccine worldwide, with more than 211 million doses administered to children and young people (from 3 to 17 years old) alone. in China,” the statement said. “The Butantan Institute, which has been working for 120 years in the service of life, is prepared to be part of yet another battle to defeat the Covid-19 virus in the country”, concluded the note.
Article amended at 3:04 pm for additional information.
The National Health Surveillance Agency (Anvisa) approved this Thursday (20) the application of the immunizing CoronaVac in children and adolescents aged between 6 and 17 years – except in cases of immunosuppressed minors (with low immunity). The decision was taken during an extraordinary meeting of the collegiate board.
Children and adolescents with comorbidities may also receive the vaccine, which will be administered in two doses, with an interval of 28 days. The vaccine is the same currently used in the immunization of adults, without any type of adaptation for a pediatric version.
The decision was unanimous. In all, five directors voted in favor of the release: Meiruze Sousa Freitas, Alex Machado Campos, Rômison Rodrigues Mota, Cristiane Rose Jourdan and Anvisa’s CEO, Antônio Barra Torres.
Through social networks, the Minister of Health, Marcelo Queiroga, commented on the approval of the emergency use of CoronaVac for the age group from 6 to 17 years. “All vaccines authorized by Anvisa are considered for the PNO [Plano Nacional de Operacionalização da Vacinação contra Covid-19]. We await the entire decision and its publication in the DOU,” he said on his Twitter account.
Butantan
By means of a note, the Butantan Institute, manufacturer of CoronaVac in partnership with the Chinese biopharmaceutical company Sinovac, informed that the authorization took place after evaluation of an application sent to Anvisa on December 15, based on safety studies and immune response from countries such as Chile, China, South Africa, Thailand and also Brazil.
“CoronaVac is scientifically proven to be the safest vaccine with the fewest adverse effects, in addition to being the most used vaccine worldwide, with more than 211 million doses administered to children and young people (from 3 to 17 years old) alone. in China,” the statement said. “The Butantan Institute, which has been working for 120 years in the service of life, is prepared to be part of yet another battle to defeat the Covid-19 virus in the country”, concluded the note.
Article amended at 3:04 pm for additional information.
